CytomX Therapeutics targets H1 2027 for Varseta-M registrational study start, projecting cash runway into late 2028.
CytomX Therapeutics announced plans to initiate a registrational trial for Varseta-M, its EpCAM-targeting antibody drug conjugate, in the first half of 2027. The company projects its cash runway will extend into the second half of 2028, providing financial flexibility for development.
Varseta-M is being developed for metastatic colorectal cancer, with management emphasizing aggressive advancement toward the registrational study. The timeline reflects CytomX’s focus on accelerating its lead candidate through clinical stages.
No immediate market reaction was disclosed during the Q2 2026 earnings call, where CEO Sean McCarthy outlined the company’s strategic priorities.